Undervalued Drug Manufacturer Stocks on NYS August 2025

August 03, 2025

Drug Manufacturers

Drug Manufacturers are engaged in pharmaceutical manufacturing or sale of a diverse line of drug and healthcare products. This industry group also includes companies engaged in the development and discovery of new dugs, and tobacco and cannabis companies.

New York Stock Exchange

The New York Stock Exchange, located in New York City, is the largest securities exchange in the world by market capitalization of its listed companies.

Our Valuation

A stock is considered undervalued if it trades at a discount to our valuation. To determine a stock’s intrinsic value, we developed an algorithm that uses 6 valuation models to determine the value of a company.* To learn more about stockcalc’s valuation methods, click here.

Undervalued Drug Manufacturers stocks

Stocks in this category are held primarily for potential income and capital appreciation.

For an in-depth look at the fundamentals and valuation of each company, try the stockcalc platform free for 30 days.

SymbolNameClose Price ($)Valuation ($)Difference (%)Average Vol (30D)Market Cap ($M)Yield (%)P/E Ratio
BHC Bausch Health Companies 4.53 7.46 64.63 1604063 1674 0.00 0.0
EBS Emergent BioSolutions 6.32 6.87 8.73 1419369 362 0.00 0.0
All data provided as at market close May 29, 2025.

Company Details

Bausch Health Companies

BHC:NYS

Close Price

4.53

Our Valuation

7.46

% Difference

64.63

Market Cap ($M)

1674

P/E Ratio

0.0

Bausch Health Companies Inc is a world-wide specialty pharmaceutical, consumer health, and medical device company with a focus on branded products for the gastroenterology, hepatology, neurology and dermatology markets. The company reports revenue in five segments: Salix; International; Solta Medical; Diversified Products and Bausch + Lomb. It generates maximum revenue from the Bausch + Lomb segment.

Access the stockcalc valuation


Emergent BioSolutions

EBS:NYS

Close Price

6.32

Our Valuation

6.87

% Difference

8.73

Market Cap ($M)

362

P/E Ratio

0.0

Emergent BioSolutions Inc offers public health products to the government and healthcare providers. Company operates in three segments namely Commercial Product, MCM Products, and Services segment. The Commercial Product Segment consisting of Nasal Spray; the MCM Products Segment consisting of Anthrax-MCM products, Smallpox-MCM products and Other Products and the Services Segment consisting of Bioservices portfolio.

Access the stockcalc valuation


Bausch Health Companies and Emergent BioSolutions are the most undervalued Drug Manufacturers stocks on the NYS. See the full list on the blog: https://www.stockcalc.com/Blog/undervalued-drug-manufacturer-stocks-nys-august-2025
Bausch Health Companies $BHC and Emergent BioSolutions $EBS are the most undervalued Drug Manufacturers stocks on the #NYS. See the full list: https://www.stockcalc.com/Blog/undervalued-drug-manufacturer-stocks-nys-august-2025
Bausch Health Companies and Emergent BioSolutions are the most undervalued Drug Manufacturers stocks on the NYS. See the full list on the blog: https://www.stockcalc.com/Blog/undervalued-drug-manufacturer-stocks-nys-august-2025

Copyright © 2016- Patchell Brook Equity Analytics Inc. All rights reserved.

Risk Disclosure: Equities trading and trading of all markets, exchanges and instruments contains substantial risk and is not for every investor. An investor could potentially lose all or more than the initial investment. Risk capital is money that can be lost without jeopardizing ones’ financial security or life style. Only risk capital should be used for trading and only those with sufficient risk capital should consider trading. Past performance is not necessarily indicative of future results. View full risk information here.